Article
FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Current cancer drug targets - 1 Jan 2020
Hogan Francesca L, Williams Victoria, Knapper Steven
Abstract excerpt
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in 30% of acute myeloid leukaemia (AML) patients at diagnosis and confer an adverse clinical prognosis. Mutated FLT3 has emerged as a viable therapeutic target and a number of FLT3-directed tyrosine kinase inhibitors have progressed through clinical development over the last 10-15 years. The last two years have seen United States Food and Drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.